Investment Analysts’ Recent Ratings Updates for Vericel (VCEL)

Several analysts have recently updated their ratings and price targets for Vericel (NASDAQ: VCEL):

  • 5/21/2019 – Vericel was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 5/11/2019 – Vericel was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States. “
  • 5/10/2019 – Vericel was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 5/8/2019 – Vericel had its price target raised by analysts at Oppenheimer Holdings Inc. from $23.00 to $32.00. They now have an “outperform” rating on the stock.
  • 4/13/2019 – Vericel was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 3/30/2019 – Vericel was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

NASDAQ:VCEL traded down $0.38 during mid-day trading on Wednesday, reaching $15.92. The company’s stock had a trading volume of 590,445 shares, compared to its average volume of 642,350. The company has a current ratio of 8.47, a quick ratio of 8.16 and a debt-to-equity ratio of 0.24. Vericel Corp has a twelve month low of $8.95 and a twelve month high of $21.00. The firm has a market cap of $692.48 million, a price-to-earnings ratio of -113.71 and a beta of 2.93.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). Vericel had a negative return on equity of 3.40% and a negative net margin of 3.51%. The firm had revenue of $21.81 million for the quarter, compared to analyst estimates of $22.51 million. During the same period last year, the company earned ($0.21) EPS. The firm’s quarterly revenue was up 21.0% on a year-over-year basis. As a group, research analysts forecast that Vericel Corp will post 0.07 earnings per share for the current fiscal year.

In other Vericel news, CFO Gerard J. Michel sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $20.02, for a total value of $200,200.00. Following the sale, the chief financial officer now directly owns 122,249 shares of the company’s stock, valued at approximately $2,447,424.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Gerard J. Michel sold 17,500 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $17.02, for a total value of $297,850.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 58,125 shares of company stock worth $1,034,900. 4.50% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC lifted its stake in shares of Vericel by 3.2% in the 4th quarter. Perceptive Advisors LLC now owns 28,090 shares of the biotechnology company’s stock valued at $488,000 after purchasing an additional 879 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Vericel by 17.1% in the 3rd quarter. Legal & General Group Plc now owns 6,443 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 943 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Vericel by 11.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,634 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 1,007 shares in the last quarter. Advisory Services Network LLC lifted its stake in shares of Vericel by 1,400.0% in the 1st quarter. Advisory Services Network LLC now owns 1,500 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Meeder Asset Management Inc. lifted its stake in shares of Vericel by 25.3% in the 1st quarter. Meeder Asset Management Inc. now owns 7,222 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,457 shares in the last quarter. 85.22% of the stock is currently owned by institutional investors and hedge funds.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Featured Story: What are Bollinger Bands?

Receive News & Ratings for Vericel Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corp and related companies with MarketBeat.com's FREE daily email newsletter.